{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T16:36:26Z","timestamp":1776443786067,"version":"3.51.2"},"reference-count":42,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T00:00:00Z","timestamp":1738281600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Dual sources of cells (DSC) with peripheral blood stem cell apheresis (PBSC) and surgical bone marrow (BM) for haploidentical hematopoietic cell transplantation (Hid\u2010HCT) are used in China and some Asian countries. The experience of the Baltimore group for haploidentical transplant with post\u2010transplant cyclophosphamide (PT\u2010Cy) and reduced\u2010intensity\u2010conditioning (RIC) regimen used BM as a source of hematopoietic stem cells.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We retrospectively analyzed 64 Hid\u2010HCT with DSC and PT\u2010Cy, RIC (<jats:italic>n<\/jats:italic>\u2009=\u200957), or myeloablative\u2010conditioning (MAC) (<jats:italic>n<\/jats:italic>\u2009=\u20097), from two public health Brazilian centers, with a median follow\u2010up of 23.3\u2009months (6.7\u201345.4).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The 49 malignant patients were 27\/46 (58.7%) beyond the first remission or with no complete response, and three patients did not complete disease status evaluation before transplant. Eight of 62 patients (12.9%) had grade 2 or more Hematopoietic Cell Transplantation\u2010Specific Comorbidity Index (HCT\u2010CI), and two patients had no HCT\u2010CI classified. Cytomegalovirus (CMV) viremia occurred in 26 of 57 (45.6%). The cumulative incidence of 100\u2010day grade III\u2010IV acute GVHD was 12.3% (7\/57), with a 95% confidence interval (CI) of 3.8% and 20.8%, and 2\u2010year moderate or severe chronic GVHD was 21.1% (11\/52; 95% CI, 10.1%\u201332.3%). The 2\u2010year relapses were 24.5% for malignant disease (12\/49; 95% CI, 12.4%\u201336.5%). The 2\u2010year overall survival (OS) probability was 54.7% (35\/64; 95% CI, 42.5%\u201366.9%). Benign diseases achieve 2\u2010year OS in 73.3% (11\/15; 95% CI, 51%\u201395.7%) of the patients. The HCT\u2010CI were significant in multivariate analyses for DFS (<jats:italic>p<\/jats:italic>\u2009=\u20090.002) and OS in uni\u2010 and multivariate analyses (both <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). The number of CD34<jats:sup>+<\/jats:sup> cells by apheresis collection was significant in multivariate analysis for DFS (<jats:italic>p<\/jats:italic>\u2009=\u20090.039).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Hid\u2010HCT using PT\u2010Cy, DSC, and RIC is a safe option for benign and malignant diseases.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cam4.70541","type":"journal-article","created":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T07:29:21Z","timestamp":1738394961000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Haploidentical Stem Cell Transplantation With Dual Source of Cells and Post\u2010Transplant Cyclophosphamide"],"prefix":"10.1002","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6683-3836","authenticated-orcid":false,"given":"Ana Marcela Rojas","family":"Fonseca\u2010Hial","sequence":"first","affiliation":[{"name":"Transplante de Medula Ossea Section Federal University of Sao Paulo\u2014UNIFESP  Sao Paulo Brazil"},{"name":"Transplante de Medula Ossea Section Hospital Santa Marcelina  Sao Paulo Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katya","family":"Parisio","sequence":"additional","affiliation":[{"name":"Transplante de Medula Ossea Section Hospital Santa Marcelina  Sao Paulo Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9862-4345","authenticated-orcid":false,"given":"Jose Salvador Rodrigues","family":"de Oliveira","sequence":"additional","affiliation":[{"name":"Transplante de Medula Ossea Section Federal University of Sao Paulo\u2014UNIFESP  Sao Paulo Brazil"},{"name":"Transplante de Medula Ossea Section Hospital Santa Marcelina  Sao Paulo Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,1,31]]},"reference":[{"key":"e_1_2_11_2_1","unstructured":"Y. T.Bolon R.Atshan M.Allbee\u2010Johnson N.Estrada\u2010Merly S. J.Lee andCIBMTR \u201cCurrent Use and Outcome of Hematopoietic Stem Cell Transplantation: CIBMTR Summary Slides \u201d2022 https:\/\/cibmtr.org\/CIBMTR\/Resources\/Summary\u2010Slides\u2010Reports."},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705445"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0564-x"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11427-016-0014-8"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-02-627786"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2008.03.005"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.72.8428"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-07-438408"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190701769673"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198706253162604"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-09-3624"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.6.2055"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-01-552984"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23150"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2012.06.019"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V70.5.1382.1382"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2012.08.014"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2015.93"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.0625"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.05.014"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2020.07.010"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-05-2004"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation\u20102010.1.237"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1203517"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1361027"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2016.215"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2009.311"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31941"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-016-0248-3"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2018.05.017"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2017.59"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2013.224"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14225"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27761"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001729"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2016.03.024"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0137390"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.4262"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-623991"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2021.05.028"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-021-01328-4"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009362"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.70541","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T12:01:28Z","timestamp":1750939288000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.70541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,31]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1002\/cam4.70541"],"URL":"https:\/\/doi.org\/10.1002\/cam4.70541","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,31]]},"assertion":[{"value":"2024-03-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70541"}}